NIH Awards Major Contract to Evotec to Manage and Operate SMR
News Sep 21, 2012
Evotec AG has announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health (NIH), Department of Health and Human Services, for the operation of a Small Molecule Repository.
The contract (funded in its entirety by NIH) covers a period of up to ten years and has a total estimated value of up to EUR 60 million (approx. USD 75 million).
The NIH Small Molecule Repository (SMR) contract will continue to provide services initiated previously under contract N01MH41001 to acquire, store, maintain, and distribute the current library collection, supporting certain NIH-supported screening Centers conducting high-throughput screening (HTS) for probe and drug discovery.
As part of continuing efforts to expand and support translational science, this contract resource will now be made available to select outside collaborators (in addition to the NIH screening efforts/programs).
Library development efforts will continue to shape, improve, and expand the collection.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “We are delighted the NIH has elected to award Evotec this long term contract which further validates our entry into compound management through our acquisition of Compound Focus Inc. in June 2011. This long term contract will be managed through our San Francisco subsidiary however we are also currently developing options to expand our compound management capabilities into the East Coast of USA and also into Europe.”
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
In a strategic search, scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019